The US Supreme Court ruled that Myriad Genetics Inc. cannot patent the BRCA genes, which are tested to check a woman's risk for breast and ovarian cancer. Photo: AP

Biotech firms fear US court's DNA ruling

The court ruled that Myriad Genetics, which sells expensive tests for the genetic markers for cancer, could not claim patents on the DNA it identified in the 1990s to develop the tests.